News | May 14, 2025
Bayer confirms 2025 targets after solid start to the year
EBITDA before special items decreases to €4.08 billion (7.4%)
EBITDA before special items decreases to €4.08 billion (7.4%)
_256_384.jpg)
The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025
Launched in Thailand, the ASEAN hub, marking an early entry into the fast-growing combination therapy market (DPP-4 and SGLT-2 inhibitor combination) with strong potential for market leadership
The Protect VL project was born out of a vision to reduce the environmental footprint of medical devices
The inspection conducted from December 16, 2024 to December 20, 2024 by the Brazil Health Regulatory Agency (ANVISA)
Tolvaptan Tablets are indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
Scores highest PAT of Rs. 118 crore in FY25
Subscribe To Our Newsletter & Stay Updated
